husband, father, medical physicist and nano-scientist, innovator and entrepreneur. opinions are my own
Strasbourg & Paris, France
Joined August 2013
- Tweets709
- Following1.7K
- Followers887
- Likes1.9K
Alex Detappe retweeted
Key insights driving ADC innovation. Thanks a lot to @FAndreMD Agathe Peltier @jsoriamd @AlxDetappe and yukinori for your important contribution
Alex Detappe retweeted
Perspective @NatureMedicine
The next generation of antibody–drug conjugates
nature.com/articles/s41591-0…
Grateful to @EricTopol for picking this up 🙏. The other half of the argument came out the same week in Advanced Materials: what conjugation costs the antibody itself, and why a program should state whether it is building a drug or a delivery vehicle.
This field is hot: the pace of innovation of antibody-conjugate drugs vs cancer is so accelerated that clinical trials can't keep up
nature.com/articles/s41591-0…
nature.com/articles/d41586-0…
Alex Detappe retweeted
The next generation of antibody–drug conjugates
We need innovation in ADCs👇
nature.com/articles/s41591-0…
Two Perspectives on antibody-drug conjugates, published days apart, one from the clinic and one from the chemistry. I am struck by how differently the same problem looks from each end.
Since the dose ceiling is set by payload toxicity, not the antibody, that loss cannot be made up by giving more. Whether it matters depends on what the antibody was there to do: a great deal for trastuzumab in HER2+ disease, far less for a pure delivery backbone.
What neither can yet say is how much the antibody still contributes once conjugated, for which targets and in which settings. No trial design in use separates that from the payload.
@GustaveRoussy #institutstrauss @ERC_Research @laliguecancer @Inserm @ParisSaclay
Thrilled to share our latest review in @ADDReditors, led by @MainakBan in collaboration with @twan_lammers, on drug delivery systems for PROTACs and molecular glue degraders ! doi.org/10.1016/j.addr.2026.…
Alex Detappe retweeted
🏆 Une nouvelle reconnaissance européenne pour la recherche menée à Gustave Roussy.
Le Pr Alexandre Detappe vient d'obtenir un financement ERC Proof of Concept pour son projet Nano-BITE, qui figure parmi les 182 projets retenus en Europe, dont seulement 18 en France. Cette distinction témoigne de l'excellence et du fort potentiel d'innovation de ses travaux.
Grâce à la nanomédecine, le projet Nano-BITE ambitionne de renforcer l'efficacité de l'immunothérapie contre les tumeurs solides en guidant plus efficacement les cellules immunitaires vers la tumeur, tout en limitant les effets sur les tissus sains.
Félicitations au Pr Alexandre Detappe et à l'ensemble des équipes de l'European Research Council (ERC), de l'Inserm, de l'Université Paris-Saclay, de l'Université de Strasbourg et de l'IMS (Institut du Médicament de Strasbourg) mobilisées autour de ce projet.
👉 Rdv sur notre site pour en savoir plus : lnkd.in/ep4YSBrb
Alex Detappe retweeted
An honor to co-launch with @tomas_pluskal the Dream Biology Award for young researchers (7 years from PhD) that comes with a €10,000 prize and trophy. dreambiologyaward.org/
stellar committee: dreambiologyaward.org/commit…
Deadline July 31, 2026.
Alex Detappe retweeted
A very impressive study for how we could prevent lung cancer more than 5 years before it is diagnosed. Using machine learning, discovery of a 14-plasma protein signature of risk that predicts responsiveness to an antibody therapy to interleukin, IL-1β
Validated across 8 cohorts
@CellCellPress @CharlesSwanton
cell.com/cell/fulltext/S0092…
New preprint on bioRxiv: Hydrogel confinement enables subcutaneous delivery of vesicant antibody-drug conjugates.
We observe that:
• Platform generalization across T-DM1, T-DXd, trastuzumab and enfortumab vedotin establishes that the determining variable is payload pharmacology rather than target or conjugate chemistry.